Similar articles

• On "Rise in Neonatal Abstinence Syndrome Rate Is Associated with Increase in Buprenorphine Prescription Numbers".

  Ghodasara SK, Yang HJ, Nemeth ZH. Ghodasara SK, et al. South Med J. 2024 Aug;117(8):510. doi: 10.14423/SMJ.0000000000001711. South Med J. 2024. PMID: 39094803 No abstract available.
• Buprenorphine compared with methadone in opioid-dependent pregnant women: How does it affect neonatal abstinence syndrome?

  Bivin B, Waring A, Alves P. Bivin B, et al. J Am Assoc Nurse Pract. 2019 Dec 4;33(2):119-125. doi: 10.1097/JXX.0000000000000345. J Am Assoc Nurse Pract. 2019. PMID: 31809398
• Use of naltrexone in treating opioid use disorder in pregnancy.

  Towers CV, Katz E, Weitz B, Visconti K. Towers CV, et al. Am J Obstet Gynecol. 2020 Jan;222(1):83.e1-83.e8. doi: 10.1016/j.ajog.2019.07.037. Epub 2019 Jul 31. Am J Obstet Gynecol. 2020. PMID: 31376396
• The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care.

  Pryor JR, Maalouf FI, Krans EE, Schumacher RE, Cooper WO, Patrick SW. Pryor JR, et al. Arch Dis Child Fetal Neonatal Ed. 2017 Mar;102(2):F183-F187. doi: 10.1136/archdischild-2015-310045. Epub 2017 Jan 10. Arch Dis Child Fetal Neonatal Ed. 2017. PMID: 28073819 Free PMC article. Review.
• Buprenorphine: a newer drug for treating neonatal abstinence syndrome.

  Bell SG. Bell SG. Neonatal Netw. 2012 May-Jun;31(3):178-83. doi: 10.1891/0730-0832.31.3.178. Neonatal Netw. 2012. PMID: 22564314 Review.